Our meta‐analysis showed that although the nivolumab group exhibited higher ORRs (19.4% vs 11.2%, P = 0.0008), it also showed higher rates of disease progression (43.3% vs 31.1%, P = 0.0003), which could be due to the following: (a) not all NSCLC issues showed sufficiently high expression of PD‐L1, which plays an important role in the function of nivolumab but does not affect docetaxel‐based chemotherapy, and (b) more or less, docetaxel‐based chemotherapy nearly always exhibited anti‐tumor efficacy for NSCLC. The gene discussed is CD274; the disease is neoplasm.